Clinical Trials Sponsored by AstraZeneca BV

Total 4576 results

Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
AstraZeneca
Acerta Pharma BV

Completed

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Infectious Disease

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Multiple Myeloma | Non-Hodgkins Lymphoma | B-All

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States, Canada, Italy
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Chronic Lymphocytic Leukemia

United States, Spain, Canada, Italy, Taiwan, Russian Federation, Turkey, Germany, Korea, Republic of, Brazil, Hungary, Poland, China, Sweden, Bulgaria, Israel, United Kingdom, Australia, Saudi Arabia, Austria, France, Czechia, South... and more
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Lymphoma, Mantle Cell

United States, France, Italy, Taiwan, Mexico, Russian Federation, Vietnam, Belgium, Canada, Brazil, Hungary, Japan, Poland, China, Spain, Germany, Australia, Czechia, Korea, Republic of, Israel, Romania, Ukraine, Argentina, Peru, New Zealand and more
Acerta Pharma BV
AstraZeneca

Terminated

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

COVID-19

Brazil
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI)

COVID-19

Italy, Turkey, Brazil, Japan, South Africa, Germany, Poland, Russian Federation, India, Peru, France, Argentina, Chile, Mexico
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI US)

COVID-19

United States
ECRI bv
AstraZeneca; The Medicines Company; Biosensors International

Completed

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Coronary Artery Disease (CAD)

Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Singapore, Spain, Switzerland, United Kingdom
CoreAalst BV

Recruiting

Precise Procedural and PCI Plan (P4) (P4)

Coronary Artery Disease

Denmark, United Kingdom, Belgium, Italy, Hungary
Univar BV

Unknown

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine

Wilson Disease

United Kingdom, Germany, Greece, Italy
ECRI bv
Cardialysis BV; Balton Sp.zo.o.

Terminated

POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI) (POLBOS LM)

Coronary Stenosis

France, Italy, Poland
Onera BV

Enrolling by invitation

Validation Study of a Patch-based PSG System

Sleep Disorder

Germany
Ureca BV

Terminated

Safety and Efficacy of the URECA CTO Device

Peripheral Vascular Disease

Netherlands
Polyganics BV

Completed

Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"

Neuroma

Netherlands, France
Ophtec BV

Completed

Clinical Trial With PRECIZON Presbyopic

Cataract | Presbyopia

Belgium, Germany, Netherlands, Spain, Turkey
Ophtec BV

Recruiting

Clinical Trial With Artiflex Presbyopic

Refractive Errors | Presbyopia | Myopia | Hyperopia | Ametropia

Korea, Republic of, Netherlands, Spain
Polyganics BV

Recruiting

Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery (ENCASE-II)

Cerebrospinal Fluid Leak

United States, Netherlands, Switzerland, Germany, Austria, Belgium, Italy
Polyganics BV

Completed

Evaluate the Safety and Performance of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery

Cerebrospinal Fluid Leak

Switzerland, Netherlands
Polyganics BV

Completed

Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma

Neuroma

United States, Spain, France, Germany, Italy, Sweden, United Kingdom
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
ECRI bv
Bayer; Rigshospitalet, Denmark; Cardialysis BV

Completed

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) (GALILEO-4D)

Cardiovascular Diseases | Thrombosis | Aortic Valve Stenosis | Heart Valve Diseases | Ventricular Outflow Obstruction

Germany, United States, Denmark, Switzerland, Netherlands, Sweden, Canada
Diabeter Nederland BV

Not yet recruiting

CloudCare in the Treatment of Type 1 Diabetes in Pediatrics

Type1diabetes | Pediatric ALL

Netherlands
GATT Technologies BV

Recruiting

GATT-Patch Versus SURGICEL® Original in Minimally Invasive Liver and Gallbladder Surgery

Liver Diseases | Gallbladder Diseases | Intraoperative Bleeding | Hemorrhage, Surgical

United States
Diabeter Nederland BV

Recruiting

Evaluation of CloudCare in the Treatment of Type 1 Diabetes

Type 1 Diabetes

Netherlands
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
Glycostem Therapeutics BV

Recruiting

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Belgium, Netherlands, Switzerland, France, Germany
Acerta Pharma BV

Active, not recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter's Syndrome

United States, United Kingdom, Italy
Acerta Pharma BV

Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Chronic Lymphocytic Leukemia

United States, United Kingdom, Belgium, Spain, Israel, France
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Concept Medicals BV

Active, not recruiting

TReAtmeNt of Small Coronary Vessels: MagicTouch Sirolimus Coated Balloon (TRANSFORM I)

Coronary Artery Disease | DCB

Ireland, Italy, United Kingdom
Acerta Pharma BV

Completed

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Healthy Participants

United States
Temple Therapeutics BV

Completed

A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions

Pelvic Adhesions

Ukraine
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Healthy Volunteers

United States
Oxytone Bioscience BV

Terminated

Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility

Post Partum Haemorrhage

Sweden
Fontem Ventures BV

Completed

A Study to Evaluate the Safety of Electronic Vapor Products for 2 Years

Healthy Volunteers

United Kingdom
Crucell Holland BV

Completed

Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines

Hepatitis A

Israel
Fontem Ventures BV

Completed

A Study to Evaluate the Pharmacokinetic Profiles of Cigarettes and E-Cigarettes With Nicotine Salt Formulations

Healthy Volunteers

United States
Oxytone Bioscience BV

Withdrawn

Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin

Healthy Women of Child Bearing Potential
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Kenya
Crucell Holland BV

Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Tanzania, Uganda
Crucell Holland BV

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Respiratory Tract Infections | Respiratory Syncytial Viruses

United States
Acerta Pharma BV

Withdrawn

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma
Delta Crystallon BV

Completed

Safety and Dose-finding Study of DC-TAB in Healthy Subjects

Multiple Sclerosis

Netherlands
Crucell Holland BV

Completed

Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients

Influenza

United States, Australia, Canada
Crucell Holland BV

Completed

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Hepatitis A

Belgium

Clinical Trials Sponsored by AstraZeneca BV

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations